Literature DB >> 19139719

PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.

Rajani Kanteti1, Vidya Nallasura, Sivakumar Loganathan, Maria Tretiakova, Todd Kroll, Soundararajan Krishnaswamy, Leonardo Faoro, Philip Cagle, Aliya N Husain, Everett E Vokes, Deborah Lang, Ravi Salgia.   

Abstract

PAX5 is a nuclear transcription factor required for B cell development, and its expression was evaluated in upper aerodigestive malignancies and pancreatic cancer by immunoblotting. The PAX5 protein expression was relatively strong in small-cell lung cancer (SCLC, 11/12); however, its expression was not detected in non-SCLC (NSCLC, n=13), mesothelioma (n=7), pancreatic (n=6), esophageal (n=6) and head and neck cancer cell lines (n=12). In comparison, PAX8 and PAX3 expressions were absent or non-detectable in SCLC cell lines; however, PAX8 was expressed in most of the tested NSCLC cell lines (13/13) and also frequently in all the other cell lines. We also detected frequent expressions of PAX2 and PAX9 protein in the various cell lines. Utilizing neuroendocrine tumor samples, we found that the frequency as well as the average intensity of the expression of PAX5 increased from pulmonary carcinoid (9%, moderate and strong PAX5 expression, n=44), to large-cell neuroendocrine carcinoma (LCNC, 27%, n=11) to SCLC (33%, n=76). FISH analysis revealed no translocations of the PAX5 gene, but polyploidy in some SCLC tumor tissues (6/37). We determined that PAX5 could regulate the transcription of c-Met using luciferase-coupled reporter and chromatin immunoprecipitation analysis. In addition, the phospho-c-Met (active form) and PAX5 were both localized to the same intra-nuclear compartment in hepatocyte growth factor treated SCLC cells and interacted with each other. Finally, we determined the therapeutic translational potential of PAX5 using PAX5 knockdown SCLC cells in conjunction with Topoisomerase 1 (SN38) and c-Met (SU11274) inhibitors. Loss of endogenous PAX5 significantly decreased the viability of SCLC cells, especially when combined with SN38 or SU11274, and maximum effect was seen when both inhibitors were used. Therefore, we propose that PAX5 could be an important regulator of c-Met transcription and a potential target for therapy in SCLC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19139719      PMCID: PMC2741690          DOI: 10.1038/labinvest.2008.168

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  46 in total

1.  Comparison of the DNA extraction methods for polymerase chain reaction amplification from formalin-fixed and paraffin-embedded tissues.

Authors:  Y Sato; R Sugie; B Tsuchiya; T Kameya; M Natori; K Mukai
Journal:  Diagn Mol Pathol       Date:  2001-12

2.  PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected].

Authors:  T G Kroll; P Sarraf; L Pecciarini; C J Chen; E Mueller; B M Spiegelman; J A Fletcher
Journal:  Science       Date:  2000-08-25       Impact factor: 47.728

3.  Nephric lineage specification by Pax2 and Pax8.

Authors:  Maxime Bouchard; Abdallah Souabni; Markus Mandler; Annette Neubüser; Meinrad Busslinger
Journal:  Genes Dev       Date:  2002-11-15       Impact factor: 11.361

4.  Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin.

Authors:  H D Foss; R Reusch; G Demel; G Lenz; I Anagnostopoulos; M Hummel; H Stein
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

5.  Sp1 and Sp3 transcription factors synergistically regulate HGF receptor gene expression in kidney.

Authors:  Xianghong Zhang; Yingjian Li; Chunsun Dai; Junwei Yang; Peter Mundel; Youhua Liu
Journal:  Am J Physiol Renal Physiol       Date:  2003-01

6.  The interaction of Pax5 (BSAP) with Daxx can result in transcriptional activation in B cells.

Authors:  Alexander V Emelyanov; Cecilia R Kovac; Manuel A Sepulveda; Barbara K Birshtein
Journal:  J Biol Chem       Date:  2002-01-17       Impact factor: 5.157

7.  PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma.

Authors:  J Anderson; A Ramsay; S Gould; K Pritchard-Jones
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

8.  Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

Authors:  Gautam Maulik; Takashi Kijima; Patrick C Ma; Sudip K Ghosh; Jeffrey Lin; Geoffrey I Shapiro; Erik Schaefer; Elena Tibaldi; Bruce E Johnson; Ravi Salgia
Journal:  Clin Cancer Res       Date:  2002-02       Impact factor: 12.531

9.  PAX-5 expression in pulmonary neuroendocrine neoplasms: its usefulness in surgical and fine-needle aspiration biopsy specimens.

Authors:  Gabriel Sica; Madeline F Vazquez; Nassar Altorki; Jeffrey Port; Paul C Lee; Yifang Liu; Elizabeth Hyjek; Anjali Saqi
Journal:  Am J Clin Pathol       Date:  2008-04       Impact factor: 2.493

10.  Progressive loss of PAX9 expression correlates with increasing malignancy of dysplastic and cancerous epithelium of the human oesophagus.

Authors:  Josef-Karl Gerber; Thomas Richter; Elisabeth Kremmer; Jerzy Adamski; Heinz Höfler; Rudi Balling; Heiko Peters
Journal:  J Pathol       Date:  2002-07       Impact factor: 7.996

View more
  35 in total

Review 1.  [Neuroendocrine tumors of the lungs. From small cell lung carcinoma to diffuse idiopathic pulmonary neuroendocrine cell hyperplasia].

Authors:  P A Schnabel; K Junker
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung.

Authors:  Jie Song; Mei Li; Maria Tretiakova; Ravi Salgia; Philip T Cagle; Aliya N Husain
Journal:  Arch Pathol Lab Med       Date:  2010-11       Impact factor: 5.534

3.  Transcriptional inhibition of intestinal NHE8 expression by glucocorticoids involves Pax5.

Authors:  Hua Xu; Bo Zhang; Jing Li; Huacong Chen; Chunhui Wang; Fayez K Ghishan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-07-29       Impact factor: 4.052

4.  JAK3 Variant, Immune Signatures, DNA Methylation, and Social Determinants Linked to Survival Racial Disparities in Head and Neck Cancer Patients.

Authors:  Rafael Guerrero-Preston; Fahcina Lawson; Sebastian Rodriguez-Torres; Maartje G Noordhuis; Francesca Pirini; Laura Manuel; Blanca L Valle; Tal Hadar; Bianca Rivera; Oluwasina Folawiyo; Adriana Baez; Luigi Marchionni; Wayne M Koch; William H Westra; Young J Kim; James R Eshleman; David Sidransky
Journal:  Cancer Prev Res (Phila)       Date:  2019-02-18

5.  PAX5 gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma.

Authors:  Keisuke Kurimoto; Masamichi Hayashi; Rafael Guerrero-Preston; Masahiko Koike; Mitsuro Kanda; Sho Hirabayashi; Hiroshi Tanabe; Nao Takano; Naoki Iwata; Yukiko Niwa; Hideki Takami; Daisuke Kobayashi; Chie Tanaka; Suguru Yamada; Goro Nakayama; Hiroyuki Sugimoto; Tsutomu Fujii; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Epigenetics       Date:  2017-11-27       Impact factor: 4.528

6.  The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

Authors:  Martin Sattler; Mamatha M Reddy; Rifat Hasina; Tara Gangadhar; Ravi Salgia
Journal:  Ther Adv Med Oncol       Date:  2011-07       Impact factor: 8.168

7.  Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.

Authors:  Katsuhiro Masago; Yosuke Togashi; Shiro Fujita; Yuichi Sakamori; Chiyuki Okuda; Young Hak Kim; Tadashi Mio; Michiaki Mishima
Journal:  Med Oncol       Date:  2011-07-21       Impact factor: 3.064

8.  B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.

Authors:  Gang Xiao; Lai N Chan; Lars Klemm; Daniel Braas; Zhengshan Chen; Huimin Geng; Qiuyi Chen Zhang; Ali Aghajanirefah; Kadriye Nehir Cosgun; Teresa Sadras; Jaewoong Lee; Tamara Mirzapoiazova; Ravi Salgia; Thomas Ernst; Andreas Hochhaus; Hassan Jumaa; Xiaoyan Jiang; David M Weinstock; Thomas G Graeber; Markus Müschen
Journal:  Cell       Date:  2018-03-15       Impact factor: 41.582

Review 9.  MET as a possible target for non-small-cell lung cancer.

Authors:  Ahad A Sadiq; Ravi Salgia
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

10.  PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells.

Authors:  Zoulika Kherrouche; Didier Monte; Elisabeth Werkmeister; Luc Stoven; Yvan De Launoit; Alexis B Cortot; David Tulasne; Anne Chotteau-Lelievre
Journal:  Mol Oncol       Date:  2015-07-15       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.